Glenmark Q1 Results: Profit declines 31% to Rs 211 crore
“We delivered a strong double digit growth in our base business during the quarter excluding the impact of COVID-related products,” Glenmark Pharmaceuticals Chairman and Managing Director Glenn Saldanha said in a regulatory filing.
